T

    Tevogen Bio Holdings Inc. (TVGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.98
    +0.09 (+1.31%)

    Market Cap: $44.86M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(4/6)
    Avg Surprise
    -50.99%
    Streak
    2 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-1.52$-2.50+39.20%Beat-1.3%
    Mar 26
    		$-1.61$-2.50+35.50%Beat+53.9%
    Dec 25
    		$-7.96$-1.50-430.67%Miss-15207.7%
    Sep 25
    		$-1.50$-3.00+50.00%Beat+13.6%
    Jun 25
    		$-1.50$-2.50+40.00%Beat-3707.1%
    Mar 25
    		$-3.50$-2.50-40.00%Miss-1245.1%
    Dec 24
    		$-0.05N/AN/ABeat+98.1%
    Sep 24
    		$-1.74N/AN/ABeat-97.0%
    Jun 24
    		$-0.04$0.00N/ABeat+93.6%
    Mar 24
    		$-0.26$0.00N/ABeat-620.4%
    Dec 23
    		$-2.77N/AN/ABeat-201.8%
    Sep 23
    		$-0.88N/AN/ABeat-3037.3%
    Jun 23
    		$-0.62N/AN/ABeat-14439.5%
    Mar 23
    		$0.05N/AN/ABeat+10100.0%
    Dec 22
    		$2.73N/AN/ABeat-
    Sep 22
    		$0.03N/AN/ABeat-
    Jun 22
    		$0.00N/AN/ABeat-
    Mar 22
    		$-0.00N/AN/ABeat-
    Sep 21
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.55EV/EBITDA18.32x
    Price/FCF-2.30xFCF Yield-43.53%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE0.00%ROIC243.43%
    Financial Health
    Debt/Equity-0.22xInterest Coverage-87.91x
    Current Ratio0.33xQuick Ratio0.33x
    Trading Statistics
    Beta0.20Avg Volume7.97K
    52-Week High$49.5052-Week Low$3.64

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.70
    SMA 20$6.66
    SMA 50$6.24
    SMA 200$10.96
    EMA 10$6.76
    EMA 20$6.60
    EMA 50$6.70
    EMA 200$14.06

    MACD

    Line: 0.17Signal: 0.13Hist: 0.04

    ADX

    ADX: 13.9+DI: 21.5-DI: 15.6

    Aroon & PSAR

    Aroon Up12.0
    Aroon DownN/A
    PSAR$7.12

    Bollinger Bands

    Upper Band$7.11
    Lower Band$6.22
    %B Position1338%(Upper)
    Band Width0.85

    RSI (14-Day)

    Neutral
    57.8

    Momentum Oscillators

    Stoch %K90.7
    Stoch %D85.9
    Williams %RN/A
    ROC (10d)6.1%
    Momentum0.40
    CCI (20d)128.1
    MFI (14d)84.4

    Volatility Measures

    ATR (14d)$0.50(7.2%)
    StdDev (20d)0.22
    Hist Vol49.4%(High)

    Volume Flow

    VWAP$6.92
    OBV2.6M
    AD Line235.1B
    CMF (20d)0.463

    Volume Metrics

    Avg Vol (20d)7.3K
    Vol Ratio1.1x
    VWMA (20d)$6.65

    Pivot Points

    R3$7.41
    R2$7.17
    R1$7.03
    Pivot Point$6.79
    S1$6.65
    S2$6.41
    S3$6.27

    Advanced Oscillators

    TSI9.84
    Ultimate Osc75.5
    KST207.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$396,586$0$0$0$0$0$0
    Cost of Revenue$60,144$59,051$85,786$27,225$290,784$103,547N/A$101,741$99,990$98,303$100,869$93,579
    Gross Profit$-60,144$-59,051$-85,786$-27,225$-290,784$-103,547N/A$-101,741$-99,990$-98,303$-100,869$-93,579
    Operating Expenses$5.60M$5.34M$4.52M$5.73M$5.44M$10.36M$9.42M$5.98M$8.50M$29.42M$1.91M$2.23M
    R&D$3.28M$3.13M$2.11M$3.11M$2.70M$3.20M$2.84M$3.26M$4.12M$20.81M$908,049$1.12M
    SG&A$2.38M$2.27M$2.50M$2.62M$2.74M$7.16M$6.59M$2.82M$4.47M$8.71M$933,394$1.21M
    Operating Income$-5,662,376$-5,400,920$-4,610,201$-5,729,431$-5,444,536$-10,356,347$-9,423,210$-6,085,527$-8,599,027$-29,516,724$-2,009,269$-2,325,008
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$98,387$71,166$70,674$62,340$38,033$24,571$15,798$12,459$6$155,786$256,031$299,943
    Income Before Tax$-5,761,940$-5,446,255$-4,677,580$-5,726,812$-5,503,979$-10,367,061$-9,504,552$-5,884,223$-9,663,447$11.26M$-3,632,232$-3,904,951
    Income Tax Expense$0$0$0$0$0$60,000$0$-5,884,223$-3,613,000$48.62M$-44,094$-39,735
    Net Income$-5,761,940$-5,446,255$-4,677,580$-5,726,812$-5,503,979$-10,367,061$-9,444,552$-5,909,428$-6,050,447$11.26M$-3,632,232$-3,904,951
    EBITDA$-5,602,232$-5,458,370$-4,521,120$-5,373,055$-5,477,387$-10,237,088N/A$-5,770,023$-9,563,457$11.52M$-3,213,838$-3,511,429
    EBIT$-5,662,376$-5,517,421$-4,606,906$-5,664,472$-5,503,979$-10,342,490$-9,423,210$-5,871,764$-9,663,447$11.42M$-3,314,707$-3,605,008
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TVGN

    News

    Tevogen Inc. Revenue Breakdown – NASDAQ:TVGNW

    The article provides a high-level overview of Tevogen Inc. (NASDAQ: TVGNW) financials on TradingView. It indicates that the market is closed with no trades and points to various financial data sections like statements, statistics, dividends, and earnings. The main content of the page appears to be navigation and platform information rather than specific financial breakdowns.

    TradingView•8/20/26•
    Neutral

    Tevogen Inc (TVGN) narrows first-half loss amid tight cash and heavy R&D

    Tevogen Inc. (TVGN) reported a narrowed net loss of $11.2 million for the first half of 2026, down from $15.9 million the previous year, primarily due to a significant reduction in general and administrative expenses. Despite this improvement, the company faces tight liquidity with $1.1 million in cash against $13.6 million in liabilities and a stockholders' deficit of $8.9 million, relying on a related-party credit facility and grant commitments for operations. Tevogen is focusing on its cell-therapy and AI-driven precision medicine programs but will not initiate new clinical trials without additional financing.

    Stock Titan•8/14/26•
    Somewhat-Bearish

    Tevogen Bio Holdings Inc (TVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Tevogen Bio Holdings Inc (TVGN), detailing its current stock price, market capitalization, and analyst ratings. Based on zero analyst ratings, the company currently holds a "Strong Buy" recommendation with a significant potential upside. The report also includes a peer comparison of other biotechnology and medical research companies.

    TradingKey•8/8/26•
    Somewhat-Bullish

    TVGN Q2'26 Earnings: revenue estimate is 0 USD

    Tevogen Inc. (TVGN) is scheduled to announce its Q2'26 earnings on August 13, 2026. The company is expected to report zero revenue for the quarter, with an anticipated EPS of -$2.54. This information provides a preview of TVGN's upcoming financial results, highlighting key estimates for investors.

    TradingView•8/7/26•
    Bearish

    Tevogen Inc. (NASDAQ: TVGN) targets huge 2024 equity pool expansion

    Tevogen Inc. (NASDAQ: TVGN) is proposing a significant expansion of its 2024 Equity Incentive Plan, seeking to add 100,000,000 shares to its reserve, making the total 103,179,028 shares. This substantial increase, approximately 15.6 times the current outstanding shares, could lead to significant dilution for existing shareholders and a potential increase in insider voting power. The proposal will be voted on at the company's 2026 annual stockholders meeting on August 24, 2026, alongside the election of directors, ratification of KPMG as the independent auditor, and an amendment to permit stockholder action by written consent.

    Stock Titan•8/3/26•
    Bearish

    Frequently Asked Questions About TVGN

    Does TVGN pay dividends?
    Tevogen Bio Holdings Inc. (TVGN) does not currently pay a regular dividend.
    What is TVGN's market cap?
    Tevogen Bio Holdings Inc. (TVGN) has a market capitalization of $44.86M with a current stock price of $6.98.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In